Here’s what you should know:
1. Allergan is studying the drug’s safety and efficacy in patients with Crohn’s disease and ulcerative colitis. Allergan is also studying how biomarkers predict treatment response.
2. Allergan is launching the studies after a phase 2 clinical trial showed brazikumab had higher anti-inflammatory response and remission rates in patients with high levels of a “key” IBD biomarker.
3. Allergan will enroll 1,140 patients in its Crohn’s disease trial starting in December. Allergan is currently enrolling up to 375 patients in its ulcerative colitis trial.
4. Allergan Chief Research and Development Officer David Nicholson said, “These programs are part of our growing focus in gastroenterology, which will become even more significant for Allergan in the coming years.”
More articles on gastroenterology:
Drs. Steven Matulis, Douglas Morgan, & more: 6 GI physicians making headlines
North Carolina finalizes plan that could spur ASC, hospital developments — 5 takeaways
Vizinet awards 5 Ambulatory Care Quality and Accountability awards — 4 insights
